Nasdaq
$1.26▼ 1.56%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $67.2MShares out 53.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 10.5After-hours26.10.06 05:144Ownership#●●●
PMV Pharmaceuticals, Inc.
Insider Matthew Joseph Eckler of PMV Pharmaceuticals, Inc. reported changes in beneficial ownership of securities on October 1, 2026. This filing is a standard Form 4 disclosure regarding insider holdings.…more
$1.26-1.56%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:043Ownership
PMV Pharmaceuticals, Inc.
Matthew Eckler, an insider at PMV Pharmaceuticals, has filed a Power of Attorney to delegate his SEC reporting obligations to designated attorneys-in-fact. This filing is an administrative procedure regarding Section 16 compliance and does not impact the company's financial position or corporate governance.…more
$1.26-1.56%vs prev closeView filingShare - 10.5Pre-market26.10.05 22:008-KKey event
PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals appointed Dr. Matthew Eckler to its Board of Directors effective October 1, 2026. The company has completed enrollment for the Phase 2 monotherapy trial of rezatapopt and plans to submit a New Drug Application (NDA) for ovarian cancer treatment in the first quarter of 2027.…more
$1.26-1.56%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.1Pre-market26.09.01 22:01Bullish#●●●#●●●#●●●
PMV Pharma Announces Positive Phase 2 Data and $50.8M Public Offering
PMV Pharmaceuticals reported promising Phase 2 interim results for its ovarian cancer drug and plans to seek FDA accelerated approval. However, the company also announced a $50.8 million public offering, leading to investor concerns regarding share dilution.…more
$1.26-1.56%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.1Pre-market26.09.01 17:04
●●●●●●●● ●●●●● ●●●●●●
PMV Pharmaceuticals has priced a public offering of 22.055 million common shares along with accompanying warrants. This significant issuance is expected to lead to shareholder dilution, negatively impacting the stock.…more
$1.26-1.56%vs prev closeShareBenzinga - 9.1Overnight26.09.01 12:03
●●●●●●●● ●●●●● ●●●●●●
PMV Pharma has priced a public offering of common stock and warrants to raise approximately $50 million in gross proceeds. The issuance of new securities may lead to shareholder dilution.…more
$1.26-1.56%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report